Landscapes / Companies
Aurinia Pharmaceuticals Inc. not checked
FollowEvery new trial, moved date and filing, and a Monday email
Drugs
2
in active trials · 4 in all
Trials
2 active
13 since 2021
Drugs2
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Calcineurin inhibitor immunosuppressant |
Approved | 2 Mar 2029Phase 4 trial completes | |||
| Next date | 2 Mar 2029 · Phase 4 trial completes | ||||
| Also tested for | Lupus Nephritis | ||||
| Open drug page | |||||
Receptor molecules, native or modified |
Phase 1/2 | 2 Mar 2029Phase 1/2 trial completes | |||
| How it works | A decoy protein that soaks up a signal molecule before it can reach the body's cells | ||||
| Next date | 2 Mar 2029 · Phase 1/2 trial completes | ||||
| Also tested for | Myasthenia Gravis, Generalized | ||||
| Open drug page | |||||
About
- No active trial
- Voclosporin Ophthalmic, VOS
- SEC filings
- None: it does not file with the US SEC
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 Industry-sponsored drug trials since 2021